3-morpholin-4-yl-2H-1,2,4-triazin-5-one

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-morpholin-4-yl-2H-1,2,4-triazin-5-one
• 英文别名: 3-morpholin-4-yl-4H-1,2,4-triazin-5-one
• 化学式: C₇H₁₀N₄O₂
• mdl: MFCD08143113
• 分子量: 182.182
• InChiKey: VMWURIRXRJRMCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  66.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-morpholin-4-yl-2H-1,2,4-triazin-5-one 在 溴 作用下， 以 水 为溶剂， 反应 8.0h， 生成 3-methyl-6-morpholin-4-yl-7H-[1,2,4]triazolo[3,4-f][1,2,4]triazin-8-one
  参考文献：
  名称：

  Heinisch,L., Journal fur praktische Chemie (Leipzig 1954), 1974, vol. 316, p. 667 - 678

  摘要：

  DOI：
• 作为产物：
  描述：

  吗啉 、 3-(甲基硫代)-1,2,4-噻嗪-5(2H)-酮 以 四氢呋喃 为溶剂， 以79 %的产率得到3-morpholin-4-yl-2H-1,2,4-triazin-5-one
  参考文献：
  名称：

  [EN] LRRK2 INHIBITORS
  [FR] INHIBITEURS DE LRRK2

  摘要：

  The present invention is directed to the compounds of Formula (I) - inhibitors of LRRK2 The inhibitors described herein can be useful in the treatment of diseases or disorders associated with LRRK2, such as Parkinson disease (PD) In particular, the invention is concerned with compounds and pharmaceutical compositions inhibiting LRRK2, methods of treating diseases or disorders associated with LRRK2, and methods of synthesizing these compounds.

  公开号：

  WO2023196720A2

文献信息

• NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP3135668A1

  公开（公告）日：2017-03-01

  This invention provides a novel disubstituted 1,2,4-triazine compound or a pharmaceutically acceptable salt thereof, which has an aldosterone synthetase inhibitory activity and is useful for preventing and/or treating various diseases or conditions associated with aldosterone; a method for preparing it; use of it; as well as a pharmaceutical composition comprising it as an active ingredient. A compound of the general formula [I]: wherein RA is, for example, a group of the following formula (A-1): wherein ring A1 is, for example, a cycloalkyl group which may be substituted, and RB is, for example, a monocyclic cycloalkyl group, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种新型二取代1,2,4-三嗪化合物或其药学上可接受的盐，该化合物具有醛固酮合成酶抑制活性，可用于预防和/或治疗与醛固酮相关的各种疾病或病症；本发明还提供了一种制备方法；本发明的用途；以及一种以本发明为活性成分的药物组合物。通式[I]的化合物： 其中RA例如为下式(A-1)的基团： 其中环 A1 例如是可被取代的环烷基、 RB例如为单环环烷基、 或其药学上可接受的盐。
• Disubstituted 1, 2, 4-triazine compound
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US10029993B2

  公开（公告）日：2018-07-24

  This invention provides a novel disubstituted 1,2,4-triazine compound or a pharmaceutically acceptable salt thereof, which has an aldosterone synthetase inhibitory activity and is useful for preventing and/or treating various diseases or conditions associated with aldosterone; a method for preparing it; use of it; as well as a pharmaceutical composition comprising it as an active ingredient. A compound of the general formula [I]: wherein RA is, for example, a group of the following formula (A-1): wherein ring A1 is, for example, a cycloalkyl group which may be substituted, and RB is, for example, a monocyclic cycloalkyl group, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种新型二取代1,2,4-三嗪化合物或其药学上可接受的盐，该化合物具有醛固酮合成酶抑制活性，可用于预防和/或治疗与醛固酮相关的各种疾病或病症；本发明还提供了一种制备方法；本发明的用途；以及一种以本发明为活性成分的药物组合物。通式[I]的化合物： 其中 RA 是例如下式（A-1）的基团： 其中，环 A1 例如是可被取代的环烷基，RB 例如是单环环烷基、 或其药学上可接受的盐。
• [EN] LRRK2 INHIBITORS<br/>[FR] INHIBITEURS DE LRRK2
  申请人：[en]BRENIG THERAPEUTICS, INC.

  公开号：WO2023196720A2

  公开（公告）日：2023-10-12

  The present invention is directed to the compounds of Formula (I) - inhibitors of LRRK2 The inhibitors described herein can be useful in the treatment of diseases or disorders associated with LRRK2, such as Parkinson disease (PD) In particular, the invention is concerned with compounds and pharmaceutical compositions inhibiting LRRK2, methods of treating diseases or disorders associated with LRRK2, and methods of synthesizing these compounds.
• Heinisch,L., Journal fur praktische Chemie (Leipzig 1954), 1974, vol. 316, p. 667 - 678
  作者：Heinisch,L.

  DOI：——

  日期：——